# EDGAR Filing Document

**Accession Number:** 0001553846
**File Stem:** 0001178913-25-003524
**Filing Date:** 2025-10
**Character Count:** 26949
**Document Hash:** c543ca7ea9e0f1d4ec6275913198829b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-25-003524.hdr.sgml**: 20251020

**ACCESSION NUMBER**: 0001178913-25-003524

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20251020

**FILED AS OF DATE**: 20251020

**DATE AS OF CHANGE**: 20251020

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RedHill Biopharma Ltd.
- **CENTRAL INDEX KEY:** 0001553846
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35773
- **FILM NUMBER:** 251402433

**BUSINESS ADDRESS:**
- **STREET 1:** 21 HA'ARBA'A STREET
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 64739
- **BUSINESS PHONE:** 972-3-541-3131

**MAIL ADDRESS:**
- **STREET 1:** 21 HA'ARBA'A STREET
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 64739

------

**** 

<br> **UNITED STATES** 

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 6-K

#### Report of Foreign Private Issuer

#### Pursuant to Rule 13a-16 or 15d-16

#### of the Securities Exchange Act of 1934
For the month of October 2025<br> Commission File No.:001-35773

### REDHILL BIOPHARMA LTD.
(Translation of registrant's name into English)

#### 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This Form 6-K (other than the third, fourth and fifth paragraphs of exhibit 99.1) is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327) and on March 25, 2025 (File No. 333-286082), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, and on August 9, 2024 (File No. 333-281417).

------

RedHill Biopharma Ltd. ("RedHill" or the "Company") today announced that it has entered into definitive agreements with Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) ("Cumberland"), relating to Talicia® (omeprazole magnesium, amoxicillin and rifabutin). The transaction was effected through Talicia Holdings Inc. ("Talicia Holdings"), a recently formed subsidiary of RedHill established to hold the global rights to Talicia® and oversee its commercialization worldwide, including through partnerships.

#### Stock Purchase Agreement
On October 17, 2025, Talicia Holdings entered into a Stock Purchase Agreement with Cumberland. Under the agreement, Cumberland will invest $4 million, payable in two equal tranches - $2 million at closing and $2 million within 12 months, to acquire a 30% equity interest in Talicia Holdings. RedHill will retain 70% ownership. Talicia Holdings will be jointly controlled by RedHill and Cumberland under accompanying governance arrangements that provide for equal board representation and joint decision-making on key matters. In addition, under a related shareholders agreement, the transfer of shares by either RedHill or Cumberland is subject to a right of refusal by the other party, and each party is subject to non-competition and non-solicitation obligations for so long as such party owns shares in Talicia Holdings.

Co-Commercialization Agreement

Concurrently, Talicia Holdings and Cumberland entered into a five-year Exclusive Joint Commercialization Agreement for Talicia® in the United States. Under the agreement, the parties will jointly commercialize Talicia® in the U.S., through a joint commercialization committee with equal representation and joint decision-making to oversee commercialization, pricing, contracting, sales and marketing activities related to Talicia®. Net revenues from U.S. sales of Talicia® will be shared equally between the parties. As part of the agreement, Talicia Holdings grants Cumberland an exclusive license to use Talicia Holdings' intellectual property solely for the joint commercialization of Talicia® under the agreement, and sublicensing or co-promotion by Cumberland requires Talicia Holdings' prior written consent.

Cumberland will deploy its national sales organization to promote Talicia® and will conduct trade operations, including handling commercialization, sales, warehousing and distribution in the U.S., in accordance with Committee-approved plans, and will fund significant commercialization activities approved by the Committee. Talicia Holdings will oversee market access, marketing, regulatory approvals, and medical affairs activities, as well as manufacturing, quality, and supply of the product, bearing the related cost of goods.

#### &nbsp;&nbsp;&nbsp;&nbsp; <br>

#### EXHIBIT INDEX

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](exhibit_99-1.htm) | [Press release dated October 20, 2025, entitled: "RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal"](exhibit_99-1.htm) |

---

------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. <br>

---

| | | |
|:---|:---|:---|
|  | REDHILL BIOPHARMA LTD. | REDHILL BIOPHARMA LTD. |
|  | (the "Registrant") | (the "Registrant") |
| Date: October 20, 2025 | By: | /s/ Dror Ben-Asher |
|  | Name: | Dror Ben-Asher |
|  | Title: | Chief Executive Officer |

---

------

## Exhibit 99.1

------

<u>**Exhibit 99.1**</u><br>

![](image00001.jpg)<br>

<br> Press Release<br>

#### RedHill's Talicia <sup>®</sup> Secures $4 Million Strategic Investment

#### and U.S. Co-Commercialization Partnership Deal
*Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) invests $4 million in exchange for a 30%* 

*ownership stake and joint control in RedHill's Talicia business*

*--*

*U.S. co-commercialization partnership designed to accelerate Talicia sales growth, leveraging* 

*Cumberland's expanded national sales promotion and marketing support, and deliver significant* 

*efficiencies through shared operational responsibility*

*--*

*Transaction reinforces RedHill's financial position to advance its broader strategic objectives*

 *--*

*Patent protected through 2042 and with eight years QIDP market exclusivity, Talicia is:*

*The #1 branded U.S. gastroenterologist-prescribed H. pylori therapy*<sup>1</sup>

*Listed first-line H. pylori therapy in American College of Gastroenterology Clinical Guidelines<sup>2</sup>*

*The only FDA-approved all-in-one, low-dose rifabutin-based H. pylori therapy addressing* 

*antibiotic resistance*

**RALEIGH, N.C., and TEL-AVIV, Israel, October 20, 2025 --** (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the signing of a strategic partnership with Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) ("Cumberland"), a specialty pharmaceuticals company with a strong gastrointestinal market presence, whereby Cumberland will invest $4 million for a 30% ownership stake in RedHill's global Talicia business. The companies will share in the financial performance and operational support for the Talicia brand with RedHill retaining 70% ownership and joint control. All other aspects of RedHill's business remain unchanged.

RedHill and Cumberland have also entered into a U.S. Talicia co-commercialization agreement with an equal sharing of the product's net revenues. Cumberland commits to significant additional investment to support Talicia's U.S. business, providing the strength of its national sales force to feature and further enhance the brand's marketing and promotional activities. The partnership is designed to deliver economies of scale and cost reductions through shared responsibility for Talicia's U.S. sales, marketing, manufacturing, supply, regulatory and administrative operations.

------

"This strategic partnership provides an excellent growth opportunity for RedHill and for Cumberland, a highly capable and driven partner with a strong gastroenterology market presence, adding a market-leading approved product to its portfolio. We believe Cumberland can help drive prescriptions and deliver revenue growth, further strengthening Talicia's U.S. market leadership," **said Dror Ben-Asher, RedHill's CEO**. "The transaction highlights the significant standalone value and commercial strength of the Talicia business, and positions RedHill to accelerate growth, reinforce its financial position and reduce costs, while continuing to advance our broader strategic objectives."

"Talicia has an outstanding product profile and represents an excellent strategic fit for Cumberland, providing us with an important growth opportunity," **said A.J. Kazimi, Cumberland's CEO.** "These arrangements with RedHill provide us with the only FDA-approved all-in-one, low-dose rifabutin-based therapy to address *H. pylori* antibiotic resistance in support of patient care. We can build on the excellent foundation RedHill has created for the product, representing a strong growth opportunity for both companies, and we are delighted to be working with them to pursue this potential."

"There is a real problem with *H. pylori* antibiotic resistance, with eradication treatment failure rates of up to 40% associated with clarithromycin-containing therapies<sup>3</sup>. Leading U.S. *H. pylori* treatment guidelines are explicit on the need to avoid using clarithromycin as part of any *H. pylori* treatment regimen without prior susceptibility testing," **said Rick Scruggs, RedHill's Chief Commercial Officer**. "Moreover, *H. pylori* is a key risk factor for gastric cancer, a cause of approximately 11,000 U.S. deaths<sup>4</sup> a year. This is despite it being reported that eradication of *H. pylori* can lead to a 75% decreased gastric cancer risk.<sup>5</sup> The need for effective *H. pylori* treatment designed to address antibiotic resistance is clear."

The transaction also supports RedHill's plan to regain compliance with Nasdaq's minimum stockholders' equity requirement and maintain its continued listing, supporting access to capital and long-term financial stability. Accordingly, as a result of this transaction, as of the date of this press release, the Company believes it has stockholder's equity in excess of the $2.5 million requirement for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). The Company intends to notify Nasdaq of its compliance status so that Nasdaq can make a determination as to whether the Company has regained compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. However, there can be no assurance that Nasdaq will determine that the Company has regained compliance with the Nasdaq continued listing standards.

RedHill is committed to expanding patient access to Talicia globally. This month we announced the licensing of Talicia for new Middle East markets in a deal worth potentially $1.8 million plus sales royalty payments, with efforts to further broaden market access and secure additional non-dilutive ex-U.S. licensing revenue streams ongoing.

Talicia is patent protected through 2042 and received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation.

------

**About *H. pylori***

*H. pylori* is a bacterial infection that affects approximately 35% of the U.S. adult population<sup>6</sup> (an estimated 1.6 million U.S. patients are treated annually) rising to more than 50% globally<sup>7</sup>. Classified by the World Health Organization (WHO) as a Group 1 carcinogen*, H. pylori* is the strongest known risk factor for gastric cancer (between 70% to 90% of cases with more than 27,000 Americans diagnosed with gastric cancer annually<sup>8</sup> and approximately 800,000 deaths globally per year), a major risk factor for peptic ulcer disease (90% of cases)<sup>9</sup> and gastric mucosa-associated lymphoid tissue (MALT) lymphoma<sup>10</sup>. Eradication of *H. pylori* is becoming increasingly difficult, with current therapies failing in approximately 25-40% of patients who remain *H. pylori*-positive due to high resistance of *H. pylori* to antibiotics, especially clarithromycin, which is still commonly used in standard combination therapies<sup>11</sup>.

**About Talicia**<sup>®</sup>

Approved by the FDA for the treatment of *H. pylori* infection in adults in November 2019, Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole). Talicia received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation and is also covered by U.S. patents extending patent protection through 2042 with additional patents and applications pending and granted in various territories worldwide. Talicia is also approved by the United Arab Emirates (UAE) Ministry of Health.

#### About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.

The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis and Pulmonary Fibrosis.

For more information on Cumberland's approved products, including full prescribing information, please visit the links to the individual product websites, which can be found on the company's website at <u>www.cumberlandpharma.com</u>.

------

#### About RedHill Biopharma
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA approved gastrointestinal drug **Talicia**<sup>®</sup>**,** for the treatment of *Helicobacter pylori (H. pylori)* infection in adults<sup>12</sup>. RedHill's key clinical late-stage development programs include: (i) **opaganib (ABC294640)**, a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, and anticancer activity, targeting multiple indications with U.S. government and academic collaborations for development for radiation and chemical exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and a Phase 2 study in prostate cancer in combination with darolutamide; (ii) **RHB-204**, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn's disease (based on RHB-104's positive Phase 3 Crohn's disease study results) and Phase 3-stage for pulmonary nontuberculous mycobacteria (NTM) disease; (iii) **RHB-107** (**upamostat**), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19 and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; and (iv) **RHB-102**, with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis and positive results from a U.S. Phase 2 study for IBS-D. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America.

More information about the Company is available at <u>www.redhillbio.com</u> / <u>X.com/RedHillBio</u>.

#### TALICIA: INDICATION AND IMPORTANT SAFETY INFORMATION
Talicia is a three-drug combination of omeprazole, a proton pump inhibitor, amoxicillin, a penicillin-class antibacterial, and rifabutin, a rifamycin antibacterial--, indicated for the treatment of *Helicobacter pylori* infection in adults.

<br> To reduce the development of drug-resistant bacteria and maintain the effectiveness of Talicia and other antibacterial drugs, Talicia should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Talicia contains omeprazole, a proton pump inhibitor (PPI), amoxicillin, a penicillin-class antibacterial and rifabutin, a rifamycin antibacterial. It is contraindicated in patients with known hypersensitivity to any of these medications, any other components of the formulation, any other beta-lactams or any other rifamycin.

Talicia is contraindicated in patients receiving rilpivirine-containing products.

Talicia is contraindicated in patients receiving delavirdine or voriconazole.

Serious and occasionally fatal hypersensitivity reactions have been reported with omeprazole, amoxicillin and rifabutin.

------

Drug-induced enterocolitis syndrome (DIES) has been reported with use of amoxicillin, a component of Talicia.

Severe cutaneous adverse reactions (SCAR) (e.g., Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN)) have been reported with rifabutin, amoxicillin, and omeprazole. Additionally, drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported with rifabutin.

Acute Tubulointerstitial Nephritis has been observed in patients taking PPIs and penicillins.

Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range from mild diarrhea to fatal colitis.

<br> Talicia may cause fetal harm. Talicia is not recommended for use in pregnancy. Talicia may reduce the efficacy of hormonal contraceptives. An additional non-hormonal method of contraception is recommended when taking Talicia.

Talicia should not be used in patients with hepatic impairment or severe renal impairment.

Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs. These events have occurred as both new onset and exacerbation of existing autoimmune disease.

The most common adverse reactions (≥1%) were diarrhea, headache, nausea, abdominal pain, chromaturia, rash, dyspepsia, oropharyngeal pain, vomiting, and vulvovaginal candidiasis.

To report SUSPECTED ADVERSE REACTIONS, contact RedHill Biopharma INC. at<br> 1-833-ADRHILL (1-833-237-4455) or FDA at 1-800-FDA-1088 or <u>www.fda.gov/medwatch</u>.

Full prescribing information for Talicia is available at <u>www.Talicia.com</u>.

------

#### Forward Looking Statements
*This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words, and include, among others, statements regarding the potential impact of Talicia. Forward-looking statements include statements regarding the strategic transaction with Cumberland and are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: the risk that the strategic transaction with Cumberland will not bring the currently anticipated benefits to RedHill's global Talicia business or to RedHill's financial position, costs or its broader strategic objectives; the Company's ability to maintain compliance with the Nasdaq Capital Market's listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia®; (v) the Company's ability to successfully commercialize and promote Talicia®; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 10, 2025. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.*

------

**Company contact:**<br> Adi Frish<br> Chief Corporate & Business Development Officer<br> RedHill Biopharma<br> +972-54-6543-112<br> <u>adi@redhillbio.com</u><br>

Category: Corporate <br>

------

<sup>1</sup> IQVIA XPO Data on file

<sup>2</sup> Chey W, Howden C, Moss S, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024;119:1730-53.

<sup>3</sup> Chey et al. Am J Gastroenterol. 2024

<sup>4</sup> https://www.cancer.org/cancer/types/stomach-cancer/about/key-statistics.html

<sup>5</sup> Kumar S, et al. Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study. Gastroenterology. 2020;158(3)

<sup>6</sup> Hooi JKY et al. Global Prevalence of *Helicobacter pylori* Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153:420-429.

<sup>7</sup> Hooi JKY, et al. Global Prevalence of Helicobacter Pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420–429.

<sup>8</sup> National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER).

<sup>9</sup> Malfertheiner, P., Camargo, M.C., El-Omar, E. et al. Helicobacter pylori infection. Nat Rev Dis Primers 9, 19 (2023). <u>https://doi.org/10.1038/s41572-023-00431-8</u>

<sup>10</sup> Hu Q et al. Gastric mucosa-associated lymphoid tissue lymphoma and *Helicobacter pylori* infection: a review of current diagnosis and management. Biomarker research 2016;4.1:15.

<sup>11</sup> Malfertheiner P. et al. Management of *Helicobacter pylori* infection - the Maastricht IV/ Florence Consensus Report, Gut 2012;61:646-664; O'Connor A. et al. Treatment of *Helicobacter pylori* Infection 2015, Helicobacter 20 (S1) 54-61; Venerito M. et al. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of *Helicobacter pylori* infection. Digestion 2013;88(1):33-45.

<sup>12</sup> Talicia<sup>®</sup> (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of *H. pylori* infection in adults. For full prescribing information, see: <u>https://www.talicia.com/</u>.

------